GS 4774

Drug Profile

GS 4774

Alternative Names: GI 13020; GS-4774; Inactivated recombinant Saccharomyces cerevisiae expressing Hepatitis B virus X, surface and core antigens (GI-13020); Tarmogen T cell immunity stimulator

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator GlobeImmune
  • Developer Gilead Sciences
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 28 Nov 2016 Gilead Sciences completes a phase I trial for Hepatitis B (Combination therapy) in New Zealand (SC) (ACTRN12615001133527)
  • 17 Nov 2016 Gilead Sciences terminates its licence for GS 4774 and returned the rights to GlobeImmune
  • 11 Nov 2016 Interim efficacy and adverse events data from a phase II trial (study 1401) in Hepatitis B (Combination therapy) presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top